| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a6b29868b1a19993ec53e37e42d08617 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate |
2018-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2d1a651c3a125d4fad60e0ac475e63c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79a5c409007229796db807c342ae02e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abca81d7a4f9f3473f4436637bcb6c1c |
| publicationDate |
2021-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112020022429-A2 |
| titleOfInvention |
addition of s1p1 receptor agonist salt and crystalline form thereof and pharmaceutical composition |
| abstract |
the present invention relates to a salt form and a crystalline form of a 1- {2-fluoro-4- [5- (4-isobutylphenyl) -1,2,4-oxadiazol-3-yl] acid drug benzyl} -3-azetidinecarboxylic (formula a) for the treatment of a disease or symptom mediated by the s1p1 receptor. also described in the present invention are a method of preparing the salt form or the crystalline form, a pharmaceutical composition of the salt form or the crystalline form and the use of the salt form or the crystalline form in the preparation of a medicament for treatment and / or prevention of a disease or symptom mediated by the s1p1 receptor. (The). |
| priorityDate |
2018-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |